We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.85 | 4.70 | 5.00 | 4.85 | 4.85 | 4.85 | 14,812 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.83M | -2.24M | -0.0042 | -11.55 | 25.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/5/2016 16:12 | Wow ! I see Shore Capital are bullish on Eden's turnaround already, forecasting £500k EBITDA by 31/12/16. From eroding cash balances pre placing, we know the company were still losing money until very recently so what does that forecast really mean ? Let's assume conservatively that Eden lost £250k first 3 months to 31/3/16 based on £1.1m loss PY), and placing costs were say £250k, that means they need to make over £1m in 9 months from 1/4/16 to 31/12/16, annualised that's £1.3m or over £100k profit per month every month til Christmas ! Where are the RNS's then ? | quazie12 | |
25/5/2016 15:51 | Thank you Prophet. Much appreciated. | lr2 | |
25/5/2016 15:45 | excellent update note from Shore Capital now out on Eden. Worth reading, but they are forecasting +ve EBITDA this year, to the tune of £0.5m, followed by £1.1m PBT next year. Cash balances are forecast to rise from £2.4m end of this year to £3.3m next year. Here is a brief snippet from the report: A positive outlook Looking ahead, we highlight the group successfully raised £2.6m post the year-end, so it is well funded in the short to medium term. As alluded to previously, management anticipates further country approvals for 3AEY in terms of Portugal and France and the discussions for a commercial arrangement for Eden’s nematicide product are expected to conclude shortly. Management is also looking to expand the global reach and IP portfolio during the year through its relationship with IV and there are a number of discussions with potential partners to evaluate the use of the group’s encapsulation technology. | the prophet | |
25/5/2016 15:34 | A gallai y pin yn cael ei glywed yn gollwng | supersonico | |
25/5/2016 14:43 | Willy froth forgot to mention Shore Cap... man up queenie make the big call or don't you think SC is acting fraudulently ?? | supersonico | |
25/5/2016 14:20 | So embarrassed by her pathetic performance BOF is back to posting rubbish in Greek, how sad! Will anyone bail her out and answer the simple questions about Terpenetech? Perhaps her Market Abusing Ostrich friend the prophet could help, if he can pull his head out of the sand an read the publicly available Companies House filings. | sweet karolina | |
25/5/2016 14:18 | λακ | supersonico | |
25/5/2016 14:06 | Σού | supersonico | |
25/5/2016 13:54 | Thanks another 6 points to me as BOF ducks the questions (none of which are all that hard), having made a complete fool of herself as usual - where did she get the idea that TW was scared into silence? More BS from Eden's paid PR flunkies or a home grown fantasy? Does anyone else want to try to help poor old BOF out with answering the questions? FRC were investigating Quindell from Mar 14 it was 15 months later that they first made anything public and their disciplinary investigation is still ongoing into all the fraud there. The wheels of justice grind slowly but surely. | sweet karolina | |
25/5/2016 12:59 | What's up BOF no clever retort translated into Greek via Google Translate? As you love your bogus points system as much as Eden loves bogus revenues, profits and investments on the balance sheet, how about earning some. An easy starter question for 1 point: At 31 Jul 15 how much cash did Terpenetech have in the bank? The harder follow up question for 5 points is: Given the answer to the easy starter question how did Terpenetech afford to pay Eden £600k for a licence 4 weeks later? The next easy starter question for 1 point is what was the NAV of Terpenetech on 31 Jul 15? The harder follow up question for 5 points is given the answer to the preceding questions how can a value for Terpenetech of over £3m be justified? If you can correctly answer all the above questions that gives you 12 points. However fail to answer or answer incorrectly and you get no points and half the points go to me (6 as I know arithmetic is not your strong point). Now that really is a good deal, you really can't say fairer than that. So over to you BOF amaze us all with your acumen as nobody is impressed by the nonsense you have tried to translate into Greek. | sweet karolina | |
25/5/2016 11:14 | Come on Sweet Karolina man up Queenie and tell me you and old frothy still consider EDEN a Fraud. I'll even give you a point to show I'm a fair woman , but I'll get the point if you don't... can't be any fairer than that can I.. Game on | supersonico | |
25/5/2016 10:21 | I agree.... | birotop | |
25/5/2016 10:06 | Μήπ | supersonico | |
25/5/2016 08:22 | Δεν μπο | supersonico | |
24/5/2016 14:12 | nothing to say about the diabolical results either BOF? How sad! The market is clearly not impressed either | sweet karolina | |
24/5/2016 13:49 | Εκα | supersonico | |
24/5/2016 11:07 | an incredible amount going on in such a small company. With cash, major partnerships, product approved and selling then the outlook here looks very positive. Theres a lot to take in from the results, but this bit in particular highlights the potential for a near-term deal with a global major re B2Y: 'In the short-term we expect to receive confirmation of product registrations for 3AEY in Portugal and France and we will further advance our application for product registration to combat powdery mildew, nematodes and molluscs, to name a few areas. In particular, we believe that we are close to concluding a commercial agreement for our nematicide product B2Y, and we look forward to updating shareholders in due course. We also expect to see a number of evaluations successfully concluded during the year. ' | the prophet | |
12/5/2016 09:30 | It's all Welsh to me! Interesting re the share count, I'm sure it'll all come out in the wash... | andy | |
12/5/2016 08:58 | Cyngor Adroddiadau ariannol LAWN 85 Days Ticker | supersonico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions